Insider Selling: Pfizer, Inc. (PFE) Insider Sells 14,700 Shares of Stock

Pfizer, Inc. (NYSE:PFE) insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. The company had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the prior year, the firm earned $0.61 earnings per share. The firm’s revenue was up .9% compared to the same quarter last year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.65%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 79.01%.

TRADEMARK VIOLATION WARNING: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/11/02/insider-selling-pfizer-inc-pfe-insider-sells-14700-shares-of-stock.html.

Institutional investors have recently bought and sold shares of the company. Altfest L J & Co. Inc. increased its position in shares of Pfizer by 67.0% during the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after acquiring an additional 43,024 shares during the period. Sphera Funds Management LTD. purchased a new stake in shares of Pfizer during the first quarter worth $13,342,000. Searle & CO. increased its position in shares of Pfizer by 92.7% during the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after acquiring an additional 38,500 shares during the period. Hartford Financial Management Inc. increased its position in shares of Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 835 shares during the period. Finally, Cadence Bank NA increased its position in shares of Pfizer by 1.4% during the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 1,428 shares during the period. 69.01% of the stock is currently owned by institutional investors and hedge funds.

PFE has been the subject of a number of recent analyst reports. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Monday, July 17th. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. UBS AG reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research note on Monday, July 31st. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Finally, Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the stock. Pfizer has a consensus rating of “Hold” and an average price target of $38.35.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Insider Buying and Selling by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit